Skip to content
Search

Latest Stories

Jr NTR and Janhvi Kapoor's 'Devara' to release in two parts

Devara stars Jr NTR, Saif Ali Khan and Janhvi Kapoor in lead roles and the first part will hit the theatres on April 5, 2024.

Jr NTR and Janhvi Kapoor's 'Devara' to release in two parts

Makers of the upcoming action film Devara on Wednesday announced that the film will be released in two parts.

Taking to social media, director Koratala Siva shared the film's update.


Rejoicing Devara fans across the globe with this big announcement, Koratala Siva said, "The film is set against the forgotten lands of coastal India and the canvas is too big. As we started shooting the film, the canvas revealed itself and started getting bigger and bigger. Every character in the film has its own weight and they need to be explored and established in depth and in detail, which we can't justify in one part. So, we took the decision to tell this big story and canvas in two parts. The story won't change in shape but will thrive in scale. One of the biggest canvases ever of Devara will be done in two parts and April 5, 2024, is just the beginning."

Devara stars Jr NTR, Saif Ali Khan and Janhvi Kapoor in lead roles and the first part will hit the theatres on April 5, 2024.

The film's music is done by Anirudh Ravichander with R Rathnavelu being the cinematographer.

The official release date of the second part of the film is still awaited.

Meanwhile, Jr NTR will also be seen in director Ayan Mukerji's next action thriller film War 2 alongside Hrithik Roshan and Kiara Advani.

Janhvi, on the other hand, will also be seen in Mr and Mrs Mahi opposite Rajkumar Rao and in Ulajh alongside Gulshan Devaiah.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less